Jennifer T. Anger

Economic Costs of Overactive Bladder in the United States

OBJECTIVES To calculate, from a societal perspective, current direct (medical and nonmedical) and indirect costs of overactive bladder (OAB) in the United States and project them to future years. Existing cost assessments of OAB in the United States are incomplete and outdated. METHODS A prevalence-based model was developed incorporating age- and sex-specific OAB prevalence rates, usage data, and productivity data. On the basis of the information gathered from the recent 5 years of the medical literature, practice guidelines, Medicare and managed care fee schedules, and expert panel input, the annual per capita and total US costs were calculated for 2007. US census population forecasts were used to project the costs of OAB to 2015 and 2020. RESULTS In 2007, average annual per capita costs of OAB were

Robotic Compared With Laparoscopic Sacrocolpopexy: A Randomized Controlled Trial

1925 (

Outcomes of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder Symptoms: A Systematic Review of the Literature

1433 in direct medical,

Complications of sling surgery among female Medicare beneficiaries.

66 in direct nonmedical, and

The Financial Burden of Stress Urinary Incontinence Among Women in the United States

426 in indirect costs). Applying these costs to the 34 million people in the United States with OAB results in total national costs of

Urinary incontinence in women

65.9 billion (billion = 1000 million), (

The Effect of Concomitant Prolapse Repair on Sling Outcomes

49.1 billion direct medical,

The Effect of Age on Outcomes of Sling Surgery for Urinary Incontinence

2.3 billion direct nonmedical, and

Women's experience with severe overactive bladder symptoms and treatment: Insight revealed from patient focus groups†

14.6 billion indirect). Average annual per capita costs in 2015 and 2020 would be

Determinants of Treatment Regret in Low-Income, Uninsured Men With Prostate Cancer

1944 and